The data displays number of medicines in development for autoimmune diseases in United States as of 2016, by all types. For arthritis there were almost 76 medicines in development and awaiting review by the U.S. Food and Drug Administration (FDA) as of September 2016.
Autoimmune arthritis | 76 |
Inflammatory bowel disease | 58 |
Psoriasis | 48 |
Lupus | 39 |
Diabetes, type1 | 34 |
Multiple sclerosis | 32 |
Scleroderma | 13 |
Sjögren's syndrome | 9 |
Neuromyelitis optica | 5 |
Myasthenia gravis | 5 |
Pemphigus | 5 |
Celiac disease | 5 |
Primary biliary cholangitis | 4 |
Immune thrombocytopenia | 4 |
Dermatomyositis | 3 |
Glomerulonephritis | 3 |
CIDP | 3 |
Other diseases | 18 |
Nonspecific diseases | 17 |